



PATENT

Present Attorney Docket No. 213839-00010


RECEIVED

AUG 01 2003
TECH CENTER 1600/2900

Certificate of Mailing

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date:

July 29, 2003


David W. Clough, Ph.D.
Reg. No. 36,107
Attorney for Applicant

Application of: McCafferty *et al.*

Serial No.: 09/417,478

Filed: October 13, 1999

For: Methods for Producing
Members of Specific
Binding Pairs

Group Art Unit: 1627

Examiner: P. Ponnaluri

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the Examiner references listed on the attached Forms PTO/SB/08A and PTO/SB/08B.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes art under 35 U.S.C. §102 or §103.


Pursuant to 37 C.F.R. § 1.97(b) (4), this Information Disclosure Statement is submitted before receipt of a first Office action on the merits after the filing of a request for continued examination under 37 C.F.R. §1.114. Therefore, no fee is believed to be due with this submission.

However, should any fees be deemed necessary in connection with the filing of this document, the Assistant Commissioner is hereby authorized to deduct any such fees from our Deposit Account No. 50-1214.

Respectfully submitted,

KATTEN MUCHIN ZAVIS ROSENMAN

By: _____


David W. Clough, Ph.D.
Registration No. 36,107

Dated: July 29, 2003


KATTEN MUCHIN ZAVIS ROSENMAN

525 W. Monroe Street, Suite 1600

Chicago, IL 60661

Telephone: (312) 902-5464

Fax: (312) 577-8736



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/417,478
		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
Examiner Name	P. Pond		
Attorney Docket Number	213839-00016		
Sheet	1	of	8

RECEIVED
AUG 01 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	A1	US-6,331,415	12-18-2001	Cabilly et al.	
	A2	US patent application 07/240,160	03-22-1990	Ladner et al.	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)				
	B1	WO 88/01649	03-10-1988	Ladner et al.		
	B2	GB9022845.3	10-19-1990	Medical Research Council		
	B3	GB9024503.6 patent application	11-12-1990	O'Brien		
	B4	GB 9104744.9 patent application	03-06-1991	O'Brien		
	B5	EP-A-0 368 684	05-16-1990	Winter		
	B6	GB9015198.6 priority document	07-10-1990	O'Brien		
	B7	GB 9022845.3 priority document	10-19-1990	Medical Research Council		
	B8	GB 9104744.9 priority document	03-06-1991	O'Brien		
	B9	GB9110549.4 priority document	05-15-1991	O'Brien		
	B10	EP-B-0 349 578 B1	11-30-1994	Ladner et al.		

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/417,478		
		Filing Date	October 13, 1999		
		First Named Inventor	McCafferty		
		Group Art Unit	1627		
		Examiner Name	P. Ponnar		
Sheet	2	of	8	Attorney Docket Number	213839-00016

RECEIVED
AUG 01 2003

TECH CENTER 1600/2900


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T²
	C1	Interlocutory Decision in Opposition Proceedings to the European Patent EP-B-0589877 dated April 15, 2002 (reference number SMW/CP9503921)	
	C2	Notice of Appeal to the European Patent EP-B-0589877 from Dyax Corp., filed June 17, 2002	
	C3	Communication from EPO on Notice of Appeal filed by Dyax, issued October 21, 2002	
	C4	Notice of Appeal to the European Patent EP-B-0589877 from BioInvent Therapeutic AB, filed June 14, 2002	
	C5	Appeal No. T0639/02-334 from BioInvent Therapeutic AB to the European Patent EP-B-0589877, filed August 22, 2002	
	C6	Notice of Appeal to the European Patent EP-B-0589877 from MorphoSys AG, filed June 20, 2002, and Grounds of the Appeal, filed August 22, 2002	
	C7	Notice of Appeal, filed June 24, 2002, and Grounds of Appeal, filed August 22, 2002, from Cambridge Antibody Technology Limited against the Decision of the Opposition Division	
	C8	Notice of Opposition to the European Patent EP-B-0589877 from BioInvent International AB, filed October 24, 2002	
	C9	Document D80 in Appeal No. T0639/02-334: HHS' Freedom of Information Act (FOIA) regulations: table of contents, 5.1, 5.2, 5.3, 5.5, 5.21, 5.22, 5.24, 5.31, 5.32, 5.33, 5.34, 5.35, 5.51, 5.61 and 5.65	
	C10	Document D81 in Appeal No. T0639/02-334: Smith Declaration	
	C11	Document D82 in Appeal No. T0639/02-334: Copy of Grant Application GM 41478 and renewal applications supplied by the DHH	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/417,378
		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
Sheet 3 of 8	Attorney Docket Number	213839-00010	

RECEIVED
AUG 01 2003
TECH CENTER 1600/2900


C12	Document D83 in Appeal No. T0639/02-334: Letter, dated August 26, 1999, from Cambridge Antibody Technology Ltd in opposition proceedings against EP 0 527 839	
C13	Document D85 in Appeal No. T0639/02-334: Proprietor's letter of November 12, 1997, and amended claims	
C14	Document D86 in Appeal No. T0639/02-334: EP 0774 511 A1	
C15	Document D87 in Appeal No. T0639/02-334: Proprietor's letter of November 15, 2000	
C16	Document D88 in Appeal No. T0639/02-334: Grounds of Appeal, dated August 22, 2002, from present opponent in opposition proceedings against EP 0589 877	
C17	Document D89 in Appeal No. T0639/02-334: OD's Written Interlocutory Decision in opposition proceedings against EP 0 589 877	
C18	Document D90 in Appeal No. T0639/02-334: Marvin & Hohn (1969). Bacteriological Rev 33(2), 172-209	
C19	Notice of Opposition to the European Patent EP-B-0589877 from Crucell Holland B.V., filed October 30, 2002	
C20	Document D13: Communication of the European Office of June 28, 2001	
C21	Document D27: Details of Smith Grant application and second and third year renewals thereof as provided by the DHHS in response to a Freedom to Information Act (FOIA) request	
C22	Notice of Opposition to the European Patent EP-B-0589877 from Dyax Corp.	
C23	Document D1: EPO register print-out for the patent application with file history information	
C24	Document D3: Claims filed with the divisional application	
C25	Document D7: Pluckthun and Skerra, "Expression of functional antibody Fv and Fab fragments in <i>Escherichia coli</i>", <i>Methods in Enzymology</i>, Vol. 178: 497-515 (1989)	
C26	Notice of Opposition to the European Patent EP-B-0589877 from MorphoSys, filed October 30, 2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/417,378
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
(use as many sheets as necessary)		Attorney Docket Number	213839-00010
Sheet	4	of	8


C27	Document D1: Genentech, US Patent Application 07/621,667, priority document to EP 92902109.5
C28	Opposition to European patent EP-B-0589877, cited opposition document D2: Nelson et al. " Filamentous phage DNA cloning vectors: a noninfective mutant with a nonpolar deletion in gene III ", <i>Virology</i> 108: 338-350 (1981)
C29	Opposition to European patent EP-B-0589877, cited opposition document D3: McCoy and Khorana " Introduction and characterization of amber mutations in the bacteriorhodopsin gene ", <i>J. Bio. Chem.</i> 258: 8456-8461 (1983)
C30	Opposition to European patent EP-B-0589877, cited opposition document D5: Bullock et al. " XL1-blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection ", <i>Bio Techniques</i> 5: 376-378 (1987)
C31	Opposition to European patent EP-B-0589877, cited opposition document D6: Schnee et al. " Construction and expression of a recombinant antibody-targeted plasminogen activator ", <i>Proc. Natl. Acad. Sci. USA</i> 84:6904-6908 (1987)
C32	Opposition to European patent EP-B-0589877, cited opposition document D15: Parmley and Smith " Felamentous fusion phage cloning vectors for the study of epitopes and design of vaccines ", <i>Adv. Exp. Med. Biol.</i> 251: 215-218 (1989)
C33	Opposition to European patent EP-B-0589877, cited opposition document D18: Chaudhary et al. " A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin ", <i>Nature</i> 339: 394-397 (1989)
C34	Opposition to European patent EP-B-0589877, cited opposition document D26: Scott and Smith " Searching for peptide ligands with an epitope library ", <i>Science</i> 249: 386-389 (1990)
C35	Opposition to European patent EP-B-0589877, cited opposition document D27: Devlin et al. " Random peptide libraries: a source of specific protein binding molecules ", <i>Science</i> 249: 404-405 (1990)

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/417,378		
		Filing Date	October 13, 1999		
		First Named Inventor	McDafferty		
		Group Art Unit	1627		
		Examiner Name	P. Ponnaluri		
Sheet	5	of	8	Attorney Docket Number	213839-00010

RECEIVED
TECH CENTER 1600/2300
JUL 31 2003


C36	Opposition to European patent EP-B-0589877, cited opposition document D37: Markland et al. "Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13" , <i>Gene</i> 109: 13-19 (1991)
C37	Opposition to European patent EP-B-0589877, cited opposition document D38: Roberts et al. "Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage" , <i>Proc. Natl. Acad. Sci. USA</i> 89: 2429-2433 (1992)
C38	Opposition to European patent EP-B-0589877, cited opposition document D39: Glockshuber et al. "The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in escherichia coli" , <i>Biochemistry</i> 31: 1270-1279 (1992)
C39	Opposition to European patent EP-B-0589877, cited opposition document D41: Kay et al. "Phage display of peptides and proteins" , A Laboratory Manual (1996)
C40	Opposition to European patent EP-B-0589877, cited opposition document D42: Proba et al. "A natural antibody missing a cysteine in Vh: consequences for thermodynamic stability and folding" , <i>J. Mol. Biol.</i> 265: 161-172 (1997)
C41	Opposition to European patent EP-B-0589877, cited opposition document D43: Proba et al. "Antibody scFv fragments without disulfate bonds made by molecular evolution" , <i>J. Mol. Biol.</i> 275: 245-253 (1998)
C42	Opposition to European patent EP-B-0589877, cited opposition document D44: Letter of 18 November 1992 to EPO in prosecution of EP-B-0 349 578
C43	Opposition to European patent EP-B-0589877, cited opposition document D45: Page 3 of EPO letter of 19 October 1993 in prosecution of EP-B-0 768 377
C44	Opposition to European patent EP-B-0589877, cited opposition document D46: Letter of 22 September 1994 to EPO in prosecution of EP-B-0 768 377

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/417,378
		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
Attorney Docket Number	213839-00010		
Sheet	6	of	8

C45	Opposition to European patent EP-B-0589877, cited opposition document D47: Extract from OD Decision in opposition proceedings against EP-B-0 201 184, 1995
C46	Opposition to European patent EP-B-0589877, cited opposition document D48: Letter of 14 February 1996 to EPO in prosecution of EP-A-0 527 839
C47	Opposition to European patent EP-B-0589877, cited opposition document D49: the Boards of Appeal of the European Patent Office decision of 8 May 1996, case number T694/92 – 3.3.4
C48	Opposition to European patent EP-B-0589877, cited opposition document D50: Extract from opposition proceeding against EP-B-0 349 578 (1996)
C49	Opposition to European patent EP-B-0589877, cited opposition document D51: Extract from OD Decision in proceedings against EP-B-0 349 578 (1998)
C50	Opposition to European patent EP-B-0589877, cited opposition document D53: Declaration of professor sir Aaron Klug, Ph.D. with exhibits, (23 June 1998)
C51	Opposition to European patent EP-B-0589877, cited opposition document D54: Scott preprint, date of availability to public unproven.
C52	Opposition to European patent EP-B-0589877, cited opposition document D55: Smith grant application, date of availability to public unproven.
C53	Opposition to European patent EP-B-0589877, late filed document D56: claim for infringement of 24 September 1998
C54	Opposition to European patent EP-B-0589877, late filed document D58: McConnell et al. “Constrained peptide libraries as a tool for finding mimotopes”, Gene 151: 115-118 (1994).
C55	Opposition to European patent EP-B-0589877, late filed document D59: two chapters of “Lambda II” (eds. Hendrix et al.) Cold Spring Harbour Laboratory, Cold Spring Harbour, New York, 19983: “A Beginner’s Guide to Lambda Biology” (Arber) and “Tail Assembly and Injection” (Katsura)

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/417,378
		Filing Date	October 13, 1999
		First Named Inventor	McCauley
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
Attorney Docket Number	213839-00010		
Sheet	7	of	8

RECEIVED
FEB 11 2003
FEB CENTER 1600/2900


C56	Opposition to European patent EP-B-0589877, late filed document D60: Parmley & Smith "Filamentous fusion phage cloning vectors for the study of epitopes and design vaccines" , <i>Adv. Exp. Med. Biol.</i> 251: 251-8 (1989). The document was not admitted to the proceedings.	
C57	Opposition to European patent EP-B-0589877, late filed document D63: Declaration of William D. Huse, MD, Ph.D. (17 August 1999). The document was not admitted to the proceedings.	
C58	Opposition to European patent EP-B-0589877, late filed document D66: Crissman & Smith, "Gene-III protein of filamentous phages: evidence for a carboxyl-terminal domain with a role in morphogenesis" , <i>Virology</i> 132: 445-455 (1994).	
C59	Opposition to European patent EP-B-0589877, late filed document D67: Declaration of Dr. Viia Valge-Archer (3 May, 2000)	
C60	Opposition to European patent EP-B-0589877, late filed document D68: Declaration of Dr. Hiroshi Ueda (3 May, 2000)	
C61	Opposition to European patent EP-B-0589877, late filed document D69: First Declaration of Dr. Rachel B. Kent (4 February, 2000). The document was objected to by patentees.	
C62	Opposition to European patent EP-B-0589877, late filed document D71: letter of patentees filed at USPTO on 16 July 1996 . The document was objected to by patentees.	
C63	Opposition to European patent EP-B-0589877, late filed document D72: letter of patentees filed at USPTO on 6 March 1997 . The document was objected to by patentees.	
C64	Opposition to European patent EP-B-0589877, late filed document D73: Opposition by CAT against EP-B-0 564 531 . The document was objected to by patentees.	
C65	Opposition to European patent EP-B-0589877, late filed document D74: Decision of EPOD on EP-B-0 201 184 . The document was objected to by patentees.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/417,378		
		Filing Date	October 13, 1999		
		First Named Inventor	McCafferty		
		Group Art Unit	1627		
		Examiner Name	P. Ponnar		
Sheet	8	of	8	Attorney Docket Number	213839-00018

RECEIVED
TECH CENTER
AUG 01 2003

C66	Opposition to European patent EP-B-0589877, late filed document D75: Declaration of Prof. Andreas Plückhun. The document was objected to by patentees.
C67	Opposition to European patent EP-B-0589877, late filed document D76: Notice of grant awarded to Smith grant application. The document was objected to by patentees.
C68	Opposition to European patent EP-B-0589877, late filed document D77: Endemann and Model " Location of filamentous phage minor coat proteins in phage and in infected cells ", <i>J. Mol. Biol.</i> 250: 496-506 (1995). The document was objected to by patentees.
C69	Opposition to European patent EP-B-0589877, late filed document D79: Extract from MorphoSys website.
C70	Opposition to European patent EP-B-0589877, late filed document D80: Written Decision dated 26 May 2000 to revoke EP-B-0436597.
C71	Opposition to European patent EP-B-0589877, late filed document D81: 2nd Declaration of Dr. Viia Valge-Archer (31 May, 2000).

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.